PMID- 37807836
OWN - NLM
STAT- Publisher
LR  - 20231009
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
DP  - 2023 Oct 9
TI  - Efficacy and safety of bone management agents administered at 12 weeks vs. 4 
      weeks in patients with bone metastases: A systematic review.
PG  - 10781552231203720
LID - 10.1177/10781552231203720 [doi]
AB  - BACKGROUND: Bone modifying agents (BMAs) have been used to prevent 
      skeletal-related events (SRE) in cancer patients with bone metastases. In this 
      meta-analysis, efficacy and adverse events (AEs) were studied based on a 
      de-escalation strategy in which the BMA dosing interval was prolonged from 4 to 
      12 weeks. METHODS: PubMed, Cochrane, ICHUSHI, and CINAHL were searched for 
      articles on BMA dosing intervals from outcomes measured were the incidence of SRE 
      and related various AEs. A quantitative meta-analysis was performed using a 
      random-effects model to calculate relative risk ratios (RRs) and 95% confidence 
      intervals (CIs). RESULT: The meta-analysis included three randomized controlled 
      studies (RCTs) of Zoledronic acid hydrate (ZA) (n = 2663) and six RCTs (n = 141) 
      on BMA other than ZA. There was no difference in the incidence of SREs when 
      comparing the dosing frequency of 12 versus 4 weeks for BMA (RR = 1.21, 95% CI 
      [0.82-1.78], p = 0.33). Further, AEs related to treatment discontinuation were 
      significantly less frequent with ZA given every 12 weeks than when given every 4 
      weeks (RR = 0.51 [0.30-0.89], p = 0.02). In particular, renal dysfunction leading 
      to grade >/=3 or discontinuation of treatment with ZA occurred significantly less 
      frequently with every 12-week dosing (RR = 0.33 [0.12-0.91], p = 0.33). 
      CONCLUSION: This meta-analysis showed no influence of BMA de-escalation on the 
      incidence of SRE; nevertheless, AEs appeared to reduce with the de-escalated 
      usage of ZA.
FAU - Sato, Junya
AU  - Sato J
AUID- ORCID: 0000-0002-2478-0190
AD  - Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, 
      Yokohama, Japan. RINGGOLD: 425003
FAU - Kodaira, Makoto
AU  - Kodaira M
AD  - Kodaira Hospital, Toda, Japan.
FAU - Harada, Hiroyuki
AU  - Harada H
AD  - Division of Oral Health Sciences, Department of Oral and Maxillofacial Surgery, 
      Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental 
      University, Bunkyo, Japan. RINGGOLD: 13100
FAU - Iguchi, Haruo
AU  - Iguchi H
AD  - Sasebo Kyosai Hospital, Sasebo, Japan. RINGGOLD: 73817
FAU - Yoshida, Taichi
AU  - Yoshida T
AD  - Department of Clinical Oncology, Akita University Graduate School of Medicine, 
      Akita, Japan. RINGGOLD: 12934
FAU - Shibata, Hiroyuki
AU  - Shibata H
CN  - Diagnosis and treatment of bone metastasis: comprehensive guideline (the 2nd 
      Edition) developing group
AD  - Department of Clinical Oncology, Akita University Graduate School of Medicine, 
      Akita, Japan. RINGGOLD: 12934
LA  - eng
PT  - Journal Article
DEP - 20231009
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
SB  - IM
OTO - NOTNLM
OT  - Bone modifying agents
OT  - adverse event
OT  - bisphosphonate
OT  - de-escalation
OT  - skeletal-related event
COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/10/09 06:42
MHDA- 2023/10/09 06:42
CRDT- 2023/10/09 04:02
PHST- 2023/10/09 06:42 [medline]
PHST- 2023/10/09 06:42 [pubmed]
PHST- 2023/10/09 04:02 [entrez]
AID - 10.1177/10781552231203720 [doi]
PST - aheadofprint
SO  - J Oncol Pharm Pract. 2023 Oct 9:10781552231203720. doi: 
      10.1177/10781552231203720.